Metraipolis › archive › dc_df4aad4ee849

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study — Europe PMC PMID:40845254

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40845254
DOI
10.1182/bloodadvances.2024014975
License (as archived)
solo-consultazione
Archived
2026-10-07T16:31:46.219Z
SHA-256 of the archived text
d3d2a26af3cdb2e43b3166e8b8706295475b1d3cb1a3badd6c32d4dc84494781
Stable URL of this page
https://metraipolis.com/documento/dc_df4aad4ee849

How to cite

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study — Europe PMC PMID:40845254 — Europe PMC (en), https://europepmc.org/article/MED/40845254 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_df4aad4ee849 (Metraipolis archive dc_df4aad4ee849, sha256 d3d2a26af3cdb2e43b3166e8b8706295475b1d3cb1a3badd6c32d4dc84494781)
BibTeX
@misc{dcdf4aad4ee849,
  title = {Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study — Europe PMC PMID:40845254},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40845254},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_df4aad4ee849; sha256 d3d2a26af3cdb2e43b3166e8b8706295475b1d3cb1a3badd6c32d4dc84494781},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40845254. Agents can read the archived copy with the MCP tool read_document.